Healthcare providers who administered a steroid to patients containing fungal meningitis should not escape liability just because the compounding pharmacy is also at fault, the plaintiffs in a multidistrict litigation case pending in Massachusetts federal court argued in court papers.
While the New England Compounding Center “and its corporate insider certainly bear responsibility” for compounding steroid methylprednisolone acetate amid “deplorable, unsanitary conditions” and causing the meningitis outbreak, “they are not the only culpable party,” the plaintiffs said in court papers.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
